First page number:
Last page number:
Glioma is one of the most common malignant tumor types of the central nervous system. It is necessary to identify biomarkers and novel therapeutic targets for glioma. The purpose of the present study was to distinguish lipid biomarkers with differential expression patterns in glioma tissues and normal brain tissues by matrix assisted laser desorption/ionization (MALDI)‑imaging and MALDI‑time of flight (TOF)‑mass spectrometry (MS). Additionally, identification of lipid biomarkers was performed to describe novel therapeutic targets for glioma treatment. A total of six tissues from three patients with glioma and three control patients with traumatic brain injury were analyzed using UltrafleXtreme MALDI‑TOF/TOF. The expression levels of 15 lipid peaks were higher in the TBT samples compared with in the GBT samples. The expression levels of another 16 lipid peaks were higher in the GBT samples compared with in the TBT samples. 14 peaks were identified as sphingomyelins using MS/MS. Additional results were also obtained from experiments using the glioma cell line U373‑MG. These results indicated that treatment with the drug desipramine (Desi) inhibited the accumulation of ceramide on the cell membranes of glioma U373‑MG cells. Treatment with Desi inhibited the activation of insulin‑like growth factor‑1 receptor and inhibited the activation of proteins in the PI3K/Akt signaling pathway.
Glioma; Matrix assisted laser desorption/ionizationimaging; Lipid biomarkers; Sphingomyelin; PI3K/Akt signaling pathway
Novel Sphingomyelin Biomarkers for Brain Glioma and Associated Regulation Research on the PI3K/Akt Signaling Pathway.
Oncology Letters, 18(6),
Available for download on Thursday, April 02, 2020